“…Considering the latest data, active immunotherapy with CAR-T cells and BsAbs will soon revolutionize the therapeutic landscape of MM; thus, the stateof-the-art frontline treatment, including the transplant program, is expected to change in the next few years. Indeed, considering on one hand both the acute toxicities of HDM, such as hematologic and gastrointestinal toxicity, infections, and the long-term toxicities, such as secondary neoplasms [93], and considering also the significant increase in deep responses with quadruplet induction therapy and the great results of CAR-T cells and BsAbs treatment (see Table 2), it is likely that in the near future HDM-ASCT will be deferred or reserved for selected cases, leading to a risk-and a response-adapted therapy, improving the patient's quality of life and survival.…”